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Abstract
Background Roux-en-Y gastric bypass (RYGB) causes sever-
al alterations in gastrointestinal function.We hypothesized that
levels of three commonly used fecal tests change after RYGB.
Methods Fecal levels of calprotectin, elastase, and alpha-1-
antitrypsin were determined in 122 patients without signs of
gastrointestinal disease 1 to 2 years after RYGB. Medians,
distribution of values, and the percentage of patients with
levels above or below reference values were determined.
Results Median fecal calprotectin level was 163.5 (<30–
1587) μg/g; in 87 % of patients, it was above the reference
value (<50 μg/g). Median fecal elastase level was 444 (<15–
647) μg/g; 13 % was below the reference value (>200 μg/g).
Median fecal alpha-1-antitrypsin level was 0.51 (<0.20–2.20)
mg/g, comparable to the reference values.
Conclusions Fecal calprotectin levels are significantly higher
than the reference value in most patients after RYGB. Fecal
elastase is significantly lower. This might indicate that the
validity of fecal calprotectin testing is impaired after RYGB
and the specificity for fecal elastase is decreased. Clinical
awareness of altered fecal markers after RYGB is essential
to prevent unnecessary diagnostic tests, such as colonoscopy.
Fecal alpha-1-antitrypsin is not influenced by RYGB.
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Introduction
Bariatric surgery is the most effective treatment for morbid
obesity in the long term. Roux-en-Y gastric bypass (RYGB)
is most commonly performed worldwide [1]. RYGB has a
restrictive effect on food intake and results in delayed mixing
of the food with bile and pancreatic enzymes. RYGB is also
known to alter the excretion and plasma concentration of sev-
eral hormones, the fecal bacterial flora, the absorption of sev-
eral drugs, and patients’ bowel habits [2–5]. Taking these
changes in gastrointestinal function after RYGB in account,
we hypothesized that the level of fecal markers might also
change. This is relevant for several fecal proteins and enzymes
that are used to screen for gastrointestinal diseases or for
follow-up of disease severity. Three commonly used fecal
tests are calprotectin, pancreatic elastase-1 (elastase), and
alpha-1-antitrypsin (A1AT). A recent article showed signifi-
cant differences in fecal levels of calprotectin and elastase
between seven patients after RYGB and obese controls [6].
Calprotectin is a protein present in most cells, but especial-
ly in the neutrophil granulocyte, where it makes up 60 % of
the cytoplasmic proteins. Neutrophils in the intestinal wall
secrete calprotectin in case of intestinal inflammation. It is
resistant against proteolysis, and after secretion, it is not
reabsorbed or metabolized in the intestine [7]. Therefore, it
is excreted in the feces and can be used to differentiate be-
tween inflammatory bowel disease (IBD) and functional com-
plaints with high sensitivity and specificity. It is also used for
IBD follow-up [8].
Elastase-1 is a pancreas-specific enzyme secreted by the
pancreas for digestion that remains stable and is not
reabsorbed throughout the intestinal tract [9]. Determination
of elastase in the feces is a cheap, reliable, and non-invasive
test and therefore generally used for diagnosing exocrine pan-
creatic insufficiency [10]. Secretion of pancreatic juices and
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bile is regulated by several different gut hormones. Those are,
in turn, secreted in response to alterations in duodenal food
content and acidity [11]. Due to the altered anatomy after
RYGB, plasma concentration of these gut hormones changes.
This can result in decreased secretion of pancreatic enzymes
such as elastase [6, 11].
Alpha-1-antitrypsin is a protein produced in the liver with
immunomodulatory effects, mainly through inhibition of neu-
trophil elastase. It is excreted in the feces in small amounts, is
not metabolized or reabsorbed in the intestine, and remains
stable in the feces when stored [12]. Before the implementa-
tion of fecal calprotectin tests, A1ATwas used in the diagnosis
and follow-up of IBD. Nowadays, it is mainly used as a mark-
er for intestinal leakage of plasma proteins, as happens in
protein-losing enteropathy [13].
This study was designed to determine fecal levels of
calprotectin, pancreatic elastase-1, and alpha-1-antitrypsin af-
ter RYGB. We hypothesized that the fecal levels of these
proteins change significantly after surgery.
Methods
We performed an observational cross-sectional study to
determine fecal values in patients after Roux-en-Y gastric
bypass. We compared these levels with the general popu-
lation and with the current reference values. The reference
values for calprotectin and elastase are not based on
healthy reference interval calculation, but are medical de-
cision limits, based on the predictive value for underlying
disease. Therefore, it is not possible to calculate a new
reference value for calprotectin and elastase with this
study design. The reference value for A1AT is based on
healthy population intervals, so it is possible to calculate a
new reference value for A1AT [12].
Consecutive patients visiting the outpatient clinic for
follow-up 1 to 2 years after RYGB were asked to participate.
This time period was chosen to make sure patients were stable
in weight and gastrointestinal symptoms, and the jejunal mu-
cosa had adapted to the new situation [14]. All patients ful-
filled the criteria for bariatric surgery of a body mass index
(BMI) of >40 kg/m2 or >35 kg/m2 with comorbidity before
surgery. All patients had a laparoscopic antegastric antecolic
RYGB with a biliopancreatic limb of 50 cm.
Exclusion criteria were any acute or chronic gastro-
intestinal disease or systemic disease involving the in-
testine. This included IBD, gastrointestinal malignancy,
chronic pancreatitis, intestinal infection, bowel resection,
radiotherapy involving the gastrointestinal area, or wa-
tery stools at time of collection. A history of cholecys-
tectomy, acute pancreatitis, gastro-enteritis, or any other
acute gastrointestinal disease was not an exclusion cri-
terion if the patient had fully recovered. It is reported
that use of a proton pump inhibitor (PPI) or non-
steroidal anti-inflammatory drug (NSAID) might influ-
ence fecal calprotectin levels [15, 16]. Patients using a
PPI or NSAID discontinued this at least 3 days prior to
feces collection. If discontinuation was not possible, pa-
tients were excluded.
The feces was collected by the patient at home using the
feces collection device Fe-Col® (Greiner Bio-One,
Kremsmünster, Austria) and delivered to the hospital within
24 h. It was stored at −20 °C, and all specimens were defrosted
and analyzed in one batch by the laboratory for clinical chem-
istry and hematology of the University Medical Center
Utrecht.
The medical ethics committee of the Slotervaart Hospital/
Reade in Amsterdam gave approval for this study
(NL49803.048.14, P1437). All patients gave written informed
consent. The study was registered in the Netherlands Trial
Register (www.trialregister.nl, number 4761).
Laboratory Methods
Calprotectin was analyzed by enzyme-linked immuno-
sorbent assay (ELISA) after preparation (Bühlmann
Laboratories AG, Schönenbuch, Switzerland). Results
are presented in microgram calprotectin per gram feces
(μg/g). The reference value for this test is <50 μg/g,
with a lower detection limit of 30 μg/g. The median
level in the population ranges from 9.3 to 31 μg/g, with
all larger studies showing a median calprotectin level
below 30 μg/g [8]. The median level in obese people
is comparable to the general population [17]. A median
of 30 μg/g in the general population was assumed for
comparison with the results of this study.
Elastase was analyzed using ELISA (ScheBo Biotec AG,
Giessen, Germany). Results are presented in microgram per
gram. The lower limit for reliable determination is 15 μg/g;
the upper limit is 500 μg/g. In case of a level of >500 μg/g, the
exact level was also determined but is known to be less reli-
able. An elastase level of less than 200 μg/g indicates exocrine
pancreatic insufficiency; less than 100 μg/g indicates severe
pancreatic insufficiency. The median level in the population is
478 μg/g [10].
For A1AT determination, feces was freeze-dried followed
by nephelometry (Siemens Healthcare Diagnostics Products
GmbH, Marburg, Germany). Results are presented in milli-
gram A1AT per gram dry feces (mg/g). An A1AT level of
more than 1.10 mg/g (54 mg/dL) is considered an indication
of gastrointestinal protein loss. The lower detection limit de-
pends on the quality of the sample and can vary between 0.20
and 0.80 mg/g. No median level in the general population is
known for A1AT; therefore, the knownmean level of 0.58mg/
g was used for comparison [18].
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Statistical Methods
Power was determined according to the Clinical and
Laboratory Standards Institute (CLSI) guideline for determi-
nation of reference values. When a reference value is deter-
mined in a population that significantly differs from the gen-
eral population, at least 120 persons should be included [19].
Therefore, we aimed to include 120 patients.
Data were analyzed using SPSS Statistics version 21 (IBM
Corp. 2012). Median, interquartile range (IQR), and total
range are given because of non-normal distribution. For levels
that were above or below the limit for reliable detection, the
result is presented as this limit.
Subsequently, subgroup analyses of sex, previous chole-
cystectomy, previous bariatric surgery, all previous abdominal
surgery combined, and recent (<7 days) versus longer discon-
tinuation of PPI were performed for all three fecal tests with
Mann-Whitney U test.
Correlations were determined for the most recent known
serum C-reactive protein (CRP) level, age, number of months
postoperative, current BMI, and percentage total weight loss
for all three fecal tests, using Spearman’s rho test.
Furthermore, the mutual correlations between the fecal tests
were determined.
Because multiple correlations and subgroup analyses were
performed for each test, Bonferroni correction was used. A p
value of <0.005 was considered statistically significant.
The median fecal levels in this study were compared with the
previously publishedmedian, ormean in case of A1AT, values in
the population using the sign (one-sample binomial) test. A p
value of <0.05 was considered statistically significant.
The reference value for A1AT was determined in accor-
dance with the CLSI guideline [19]. Outliers were first iden-
tified and removed using the method described by Dixon [20].
The 97.5th percentile was considered the reference value. The
90 % confidence interval was identified using the rank meth-
od, with the highest rank number and the seventh highest rank
number representing the upper and lower limit of the confi-
dence interval [21].
Results
Between October and December 2014, 122 patients were includ-
ed. Characteristics of the included patients are shown in Table 1.
Calprotectin
The median calprotectin level was 163.5 μg/g, ranging from
<30 μg/g in ten participants to 1587 μg/g. One hundred four
patients (87.4 %) had a calprotectin level above the current
reference value of 50 μg/g (Table 2; Fig. 1). The median fecal
calprotectin level was significantly different from the previ-
ously published median level in the general and obese popu-
lation of 30 μg/g (p<0.001). Subgroup analyses revealed no
differences in median calprotectin levels between groups
(Table 3). There was no correlation with any of the patient
Table 1 Patient characteristics
N (%)
Sex: female/male 108 (88.5 %)/14 (11.5 %)
PPI discontinued <7 days 79 (64.8 %)
Prior bariatric surgery 12 (9.8 %)
Cholecystectomy 26 (21.3 %)
Total prior abdominal surgery 55 (45.1 %)
Median (range)
Age (years) 47 (24–64)
Time postoperative (months) 13 (12–24)
Current weight (kilogram) 82.1 (53–134)
Total weight loss (%) 31.6 (5.7–51.0)
CRP serum level (mg/l) 1.1 (0.1–32.8)
Subgroups are presented in number of patients (N) and percentages in
parentheses (%). Continuous data is expressed as median and range in
parentheses
PPI proton pump inhibitor, CRP C-reactive protein
Table 2 Results of fecal tests
Calprotectin (μg/g) Elastase (μg/g) Alpha-1-antitrypsin (mg/g)
Number of patients 122 122 115
Median 164 444 0.51
Minimum <30 <15 <0.20
Percentiles
25 95 339 0.30
75 257 545 0.80
Maximum 1587 647 2.20
Regular reference value <50 >200 <1.10
Alpha-1-antitrypsin level could not be determined reliably in seven patients
μg/g microgram per gram feces, mg/g milligram per gram dry feces
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characteristics (Table 4), but there was a significant correlation
with the fecal A1AT level (rho=0.492, p<0.001).
Elastase
The median elastase level was 443.5 μg/g, ranging from
<15 μg/g in three patients to 647 μg/g, significantly lower
than the median value of 478 μg/g in the general popula-
tion (p<0.001). Sixteen patients (13.1 %) had an elastase
level below the cutoff of 200 μg/g; in 14 (11.5 %) of
these patients, it was below 100 μg/g (Table 2). When
patients with a level of <200 μg/g were excluded, the
median value was 459 μg/g, still significantly lower than






















Fig. 1 Boxplots of calprotectin,
elastase, and alpha-1-antitrypsin.
Normal range is presented in
dark. Outliers (1 for alpha-1-
antitrypsin, 3 for calprotectin, 8
for elastase) are not shown
Table 3 Subgroup analyses
Calprotectin (μg/g) Elastase (μg/g) Alpha-1-antitrypsin (mg/g)
Median (IQR) Median (IQR) Median (IQR)
Sex Female 185 (97–264) p= 0.15 444 (363–524) p= 0.18 0.55 (0.31–0.80) p= 0.37
Male 130 (91–190) 362 (249–490) 0.43 (0.24–0.66)
PPI discontinued ≤7 days 191 (98–270) p= 0.23 443 (341–519) p= 0.95 0.58 (0.34–0.80) p= 0.35
>7 days 158 (79–237) 444 (332–530) 0.45 (0.23–0.81)
Cholecystectomy Yes 193 (135–302) p= 0.12 481 (350–545) p= 0.18 0.60 (0.49–0.80) p= 0.15
No 162 (89–254) 435 (334–507) 0.48 (0.24–0.81)
Prior bariatric surgery Yes 196 (115–304) p= 0.41 515 (398–562) p= 0.16 0.46 (0.31–0.72) p= 0.58
No 164 (93–256) 443 (333–510) 0.56 (0.30–0.81)
Any prior abdominal surgery Yes 208 (89–270) p= 0.54 464 (326–544) p= 0.53 0.57 (0.36–0.80) p= 0.31
No 147 (106–234) 438 (342–490) 0.48 (0.20–0.81)
Data expressed in median and interquartile range (IQR). p value was calculated withMann-WhitneyU. p< 0.005 was considered statistically significant
PPI proton pump inhibitor, μg/g microgram per gram feces, mg/g milligram per gram dry feces
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Subgroup analyses revealed no differences in median elas-
tase levels between groups (Table 3). No correlation with any
of the patient characteristics was found (Table 4), and there
was no correlation with the fecal A1AT (rho=0.101, p=0.28)
or calprotectin level (rho=0.001, p=0.99).
Alpha-1-Antitrypsin
Alpha-1-antitrypsin was measured in 120 patients. Two cases
were excluded because there was not enough material for
reliable testing. In five cases, the A1AT level was <0.80 mg/
g, but could not be determinedmore exactly due to insufficient
quality of the sample. These cases were not used for determi-
nation of the median and reference value. The median A1AT
level was 0.51 mg/g, ranging from <0.20 mg/g in 24 patients
to 2.20 mg/g (Table 2). This did not differ from the mean level
in the general population (p=0.19). Six patients (5.2 %) had
an A1AT level higher than the reference value of 1.10 mg/g.
Subgroup analysis revealed no significant differences between
groups (Table 3). Correlation testing was positive for fecal
calprotectin level only, as previously mentioned (Table 4).
After removal of one outlier, a reference value of 1.14mg/g
(90 % confidence interval 1.08–1.27) was determined for
A1AT.
Conclusions
In this study, we found significantly higher levels of fecal
calprotectin and lower levels of fecal elastase in patients
who underwent RYGB, compared to the general population.
The level of fecal alpha-1-antitrypsin was comparable to the
general population.
Calprotectin
The median calprotectin level in our study is 163.5 μg/g, and
87 % of patients had a level above the decision limit of
<50 μg/g. We believe this influences the validity of the fecal
calprotectin test in the RYGB population. When the current
decision limit is maintained for patients who underwent
RYGB, a high amount of endoscopies will be performed,
which might be unnecessary. It is important that clinicians
are aware of this.
There are several possible explanations for the elevation of
fecal calprotectin. We hypothesize that the elevated fecal
calprotectin levels after RYGB indicate persistent low-grade
inflammation or increased epithelial cell turnover in the gas-
trointestinal tract. This is supported by the positive correlation
with alpha-1-antitrypsin [7, 18]. The location and origin of
this possible inflammation is unclear. It is also unknown
whether surgical alterations of the gastrointestinal anatomy
other than RYGB also influence the fecal calprotectin level.
RYGB causes hyperplasia of the jejunal mucosa of the Roux-
limb, but no macroscopic or histologic evidence of inflamma-
tion is found in the majority of patients [14, 22]. An increased
inflammatory state can be found in the stomach remnant, and
more than half of the patients have chronic gastritis in this
remnant [23–25]. However, studies in non-RYGB patients
with gastritis found no increase in fecal calprotectin [26].
Another option is that inflammation in the biliopancreatic
limb causes the elevated calprotectin. There are no studies
describing the macroscopic or histologic appearance of this
blind loop. Inflammation in this part of the intestine could
be due to the deleterious effect of bile acids and pancreatic
enzymes. These are not buffered by ingested food, as would
happen in the normal anatomy, and are known to cause dam-
age to the enterocytes [27]. Inflammationmight also be caused
by bacterial overgrowth in the stomach remnant or the
biliopancreatic limb [28]. In non-RYGB patients, small intes-
tinal bacterial overgrowth did not cause an increase in fecal
calprotectin [29], but other studies showed that the fecal
calprotectin level can change when there are significant
changes in gut microbiota [30]. The colon does not seem the
most likely location for the increased calprotectin excretion, as
its anatomy is not altered in RYGB. However, there are per-
sistent pro-inflammatory changes in the rectum after RYGB
[31]. It is possible that the elevation of fecal calprotectin is a
sign of low-grade colonic inflammation, in line with these
findings.
We feel that methodological errors are unlikely. Calprotectin
was collected and stored according to current standards. It is
Table 4 Correlationswith patient
characteristics Calprotectin Elastase Alpha-1-antitrypsin
Age 0.004 (p = 0.96) −0.066 (p= 0.47) 0.258 (p= 0.005)
Time postoperative 0.104 (p = 0.25) −0.072 (p= 0.43) 0.021 (p= 0.83)
CRP serum level 0.052 (p = 0.57) 0.066 (p= 0.48) 0.050 (p= 0.60)
Current weight −0.022 (p= 0.81) −0.093 (p= 0.31) −0.051 (p = 0.59)
Percentage total weight loss −0.074 (p= 0.42) 0.031 (p= 0.74) −0.123 (p = 0.19)
Current BMI 0.046 (p = 0.62) −0.099 (p= 0.28) −0.016 (p = 0.86)
Correlations calculated with Spearman’s rho. p < 0.005 was considered statistically significant
CRP C-reactive protein, BMI body mass index
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known to remain stable for several days at room temperature and
longer when frozen [7]. All fecal tests were done in one batch by
the same experienced laboratory. All patients had undergone
surgery at least 1 year prior to inclusion and had no severe
gastrointestinal complaints. Strict exclusion criteria were set for
major factors that influence calprotectin levels, but not for factors
such as age, fiber intake, and physical activity that are known to
have only minimal influence [32, 33]. PPI and NSAID use can
influence calprotectin; therefore, these drugs were discontinued
for at least 3 days prior to feces collection. Subgroup analysis of
patients who discontinued the PPI for 3–7 days versus thosewho
had stopped PPI use for more than 7 days before collection
revealed no significant difference in fecal calprotectin levels.
Only five patients occasionally used NSAIDs prior to feces col-
lection. Calprotectin level in these patients did not differ from
patients who never used NSAIDs. Furthermore, calprotectin
levels did not correlate with the current BMI, percentage total
weight loss, or age in this study.
The determination of a new decision limit for calprotectin
after RYGB is not possible based on this study. A large cohort
of RYGB patients diagnosed postoperatively with IBD would
be needed for this. In practice, when the prevalence of IBD is
taken into account, this is not a feasible study design.
Elastase
The median fecal elastase level is lower in patients after
RYGB than in the general population, as was also
found in a previous study [6]. However, the majority
of patients had a level above the limit for pancreatic
insufficiency. None of the 16 patients (13 %) with a
fecal elastase level below the reference value had clin-
ical or biochemical evidence of pancreatic insufficiency.
Therefore, it is possible that the specificity after RYGB
is lower than the known specificity of 90–93 % in the
general population [10]. This can only be confirmed by
performing invasive pancreatic function tests in these
patients, which was not done in the course of this study.
There was evidently no correlation between fecal
calprotectin and elastase in this study, contrary to previous
findings [6, 34]. This may be explained by a smaller study
group and the selection of patients with pancreatic diseases in
these previous studies.
Alpha-1-Antitrypsin
The reference value and the median in the study population
did not differ significantly from the current reference value of
1.10 mg/L and the median in the general population. We thus
conclude that the reliability of the fecal A1AT test is not im-
paired after RYGB.
Limitations
This study has several limitations. No comparison is possible
with preoperative fecal values of the participants due to the
cross-sectional design. However, we deem it unlikely that all
patients already had elevated calprotectin levels before sur-
gery as these patients had no gastrointestinal disease prior to
RYGB. Previous studies concerning calprotectin levels in
obese patients never showed levels as high as observed in this
study [17, 33]. Second, no endoscopy, invasive pancreatic
function tests, or radiological examinations were performed
in this study. These tests might have clarified some of the
questions this study raises and should certainly be included
in future studies. Strict inclusion and exclusion criteria were
set to prevent confounding. This means that the results cannot
be transferred directly to the whole RYGB population at
whichever period postoperative. Despite the limitations, we
believe the results of this study are apparent enough to ques-
tion the validity of the current decision limit for fecal
calprotectin, and to a lesser extent elastase, in patients who
underwent RYGB.
Compliance with Ethical Standards
Conflict of Interest Dennis CW Poland is a shareholder in the
Col-Group, which is the producer of the Fe-Col®. The other authors have
no conflicts of interest to disclose.
Ethical Approval The medical ethics committee of the Slotervaart
Hospital/Reade in Amsterdam gave approval for this study
(NL49803.048.14, P1437). All procedures performed in studies involv-
ing human participants were in accordance with the ethical standards of
the institutional and/or national research committee and with the 1964
Helsinki Declaration and its later amendments or comparable ethical
standards.
Statement of Informed Consent Informed consent was obtained from
all individual participants included in the study.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Angrisani L, Santonicola A, Iovino P, Formisano G, Buchwald H,
Scopinaro N. Bariatric surgery worldwide 2013. Obes Surg. 2015.
doi:10.1007/s11695-015-1657-z.
2. Padwal R, Brocks D, Sharma AM. A systematic review of drug
absorption following bariatric surgery and its theoretical implica-
tions. Obes Rev. 2010;11(1):41–50. doi:10.1111/j.1467-789X.
2009.00614.x.
OBES SURG (2016) 26:2974–2980 2979
3. Ionut V, Burch M, Youdim A, Bergman RN. Gastrointestinal hor-
mones and bariatric surgery-induced weight loss. Obesity (Silver
Spring). 2013;21(6):1093–103. doi:10.1002/oby.20364.
4. Sweeney TE, Morton JM. Metabolic surgery: action via hormonal
milieu changes, changes in bile acids or gut microbiota? A summa-
ry of the literature. Best Pract Res Clin Gastroenterol. 2014;28(4):
727–40. doi:10.1016/j.bpg.2014.07.016.
5. Ballem N, Yellumahanthi K, Wolfe M, Wesley MM, Clements RH.
Gastrointestinal symptom improvement after Roux-en-Y gastric
bypass: long-term analysis. Surg Obes Relat Dis. 2009;5(5):553–
8. doi:10.1016/j.soard.2008.11.013.
6. Carswell KA, Vincent RP, Belgaumkar AP, Sherwood RA, Amiel
SA, Patel AG, et al. The effect of bariatric surgery on intestinal
absorption and transit time. Obes Surg. 2014;24(5):796–805. doi:
10.1007/s11695-013-1166-x.
7. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H.
Assessment of the neutrophil dominating protein calprotectin
in feces. A methodologic study. Scand J Gastroenterol.
1992;27(9):793–8.
8. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomark-
er of intestinal inflammation in inflammatory bowel disease.
Inflamm Bowel Dis. 2006;12(6):524–34.
9. Sziegoleit A, Krause E, Klor HU, Kanacher L, Linder D. Elastase 1
and chymotrypsin B in pancreatic juice and feces. Clin Biochem.
1989;22(2):85–9.
10. Naruse S, Ishiguro H, Ko SB, Yoshikawa T, Yamamoto T,
YamamotoA, et al. Fecal pancreatic elastase: a reproduciblemarker
for severe exocrine pancreatic insufficiency. J Gastroenterol.
2006;41(9):901–8. doi:10.1007/s00535-006-1884-0.
11. Ito C, Mason EE. Gastric bypass and pancreatic secretion. Surgery.
1971;69(4):526–32.
12. Wilson CM, McGilligan K, Thomas DW. Determination of fecal
alpha 1-antitrypsin concentration by radial immunodiffusion: two
systems compared. Clin Chem. 1988;34(2):372–6.
13. Strygler B, Nicar MJ, Santangelo WC, Porter JL, Fordtran JS.
Alpha 1-antitrypsin excretion in stool in normal subjects and in
patients with gastrointestinal disorders. Gastroenterology.
1990;99(5):1380–7.
14. Spak E, Bjorklund P, Helander HF, Vieth M, Olbers T, Casselbrant
A, et al. Changes in the mucosa of the Roux-limb after gastric
bypass surgery. Histopathology. 2010;57(5):680–8. doi:10.1111/j.
1365-2559.2010.03677.x.
15. Poullis A, Foster R, Mendall MA, Shreeve D, Wiener K. Proton
pump inhibitors are associated with elevation of faecal calprotectin
and may affect specificity. Eur J Gastroenterol Hepatol. 2003;15(5):
573–4. author reply 4.
16. Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth
A, et al. High prevalence of NSAID enteropathy as shown by a
simple faecal test. Gut. 1999;45(3):362–6.
17. Kant P, Fazakerley R, Hull MA. Faecal calprotectin levels before
and after weight loss in obese and overweight subjects. Int J Obes
(Lond). 2013;37(2):317–9. doi:10.1038/ijo.2012.38.
18. Fischbach W, Becker W, Mossner J, Koch W, Reiners C. Faecal
alpha-1-antitrypsin and excretion of 111indium granulocytes in as-
sessment of disease activity in chronic inflammatory bowel dis-
eases. Gut. 1987;28(4):386–93.
19. Clinical and Laboratory Standards Institute; Defining, Establishing,
and Verifying Reference Intervals in the Clinical Laboratory;
Guideline—Third Edition. CLSI document EP28-A3c.: Wayne,
PA; 2008.
20. Dixon WJ. Processing data for outliers. Biometrics.
1953;9(1):74–89.
21. Reed AH, Henry RJ, Mason WB. Influence of statistical method
used on the resulting estimate of normal range. Clin Chem.
1971;17(4):275–84.
22. Csendes A, Smok G, Burgos AM. Endoscopic and histologic find-
ings in the gastric pouch and the Roux limb after gastric bypass.
O b e s S u r g . 2 0 0 6 ; 1 6 ( 3 ) : 2 7 9 – 8 3 . d o i : 1 0 . 1 3 8 1 /
096089206776116507.
23. Safatle-Ribeiro AV, Petersen PA, Pereira Filho DS, Corbett CE,
Faintuch J, Ishida R, et al. Epithelial cell turnover is increased in
the excluded stomach mucosa after Roux-en-Y gastric bypass for
morbid obesity. Obes Surg. 2013;23(10):1616–23. doi:10.1007/
s11695-013-0975-2.
24. Faintuch J, Ishida RK, Jacabi M, Ribeiro AS, Kuga R, Sakai P, et al.
Increased gastric cytokine production after Roux-en-Y gastric by-
pass for morbid obesity. Arch Surg. 2007;142(10):962–8. doi:10.
1001/archsurg.142.10.962.
25. Flickinger EG, Sinar DR, Pories WJ, Sloss RR, Park HK, Gibson
JH. The bypassed stomach. Am J Surg. 1985;149(1):151–6.
26. Montalto M, Gallo A, Ianiro G, Santoro L, D’Onofrio F, Ricci R,
et al. Can chronic gastritis cause an increase in fecal calprotectin
concentrations? World J Gastroenterol. 2010;16(27):3406–10.
27. Tabaqchali S, Booth CC. Jejunal bacteriology and bile-salt metab-
olism in patients with intestinal malabsorption. Lancet.
1966;2(7453):12–5.
28. Ishida RK, Faintuch J, Ribeiro AS, Ribeiro Jr U, Cecconello I.
Asymptomatic gastric bacterial overgrowth after bariatric surgery:
are long-term metabolic consequences possible? Obes Surg.
2014;24(11):1856–61. doi:10.1007/s11695-014-1277-z.
29. Montalto M, Santoro L, Dalvai S, Curigliano V, D’Onofrio F,
Scarpellini E, et al. Fecal calprotectin concentrations in patients
with small intestinal bacterial overgrowth. Dig Dis. 2008;26(2):
183–6. doi:10.1159/000116777.
30. ZimmermannMB, Chassard C, Rohner F, N’Goran EK, Nindjin C,
Dostal A, et al. The effects of iron fortification on the gut microbiota
in African children: a randomized controlled trial in Cote d’Ivoire.
Am J Clin Nutr. 2010;92(6):1406–15. doi:10.3945/ajcn.110.
004564.
31. Kant P, Sainsbury A, Reed KR, Pollard SG, Scott N, Clarke AR,
et al. Rectal epithelial cell mitosis and expression of macrophage
migration inhibitory factor are increased 3 years after Roux-en-Y
gastric bypass (RYGB) for morbid obesity: implications for long-
term neoplastic risk following RYGB. Gut. 2011;60(7):893–901.
doi:10.1136/gut.2010.230755.
32. Joshi S, Lewis SJ, Creanor S, Ayling RM. Age-related faecal
calprotectin, lactoferrin and tumour M2-PK concentrations in
healthy volunteers. Ann Clin Biochem. 2010;47(Pt 3):259–63.
doi:10.1258/acb.2009.009061.
33. Poullis A, Foster R, Shetty A, Fagerhol MK, Mendall MA. Bowel
inflammation as measured by fecal calprotectin: a link between
lifestyle factors and colorectal cancer risk. Cancer Epidemiol
Biomarkers Prev. 2004;13(2):279–84.
34. Pezzilli R, Barassi A, Morselli-Labate AM, Fantini L, Tomassetti P,
Campana D, et al. Fecal calprotectin and elastase 1 determinations
in patients with pancreatic diseases: a possible link between pan-
creatic insufficiency and intestinal inflammation. J Gastroenterol.
2007;42(9):754–60. doi:10.1007/s00535-007-2086-0.
2980 OBES SURG (2016) 26:2974–2980
